Ariad shares dive after Sanders' attack

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) fell $1.93 (15%) to $11.14 on Friday after Sen. Bernie Sanders (I-Vt.) criticized the company's pricing strategy for leukemia drug Iclusig ponatinib. In a Twitter post, Sanders linked to a media report describing four price hikes in 2016, leading to a cumulative 27% increase in the drug's price this year.

"Drug corporations' greed is unbelievable," Sanders' tweet read. "Ariad has raised the price of a leukemia drug to almost $199,000 a year." ...